Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Retained Earnings (2022 - 2025)

Entrada Therapeutics has reported Retained Earnings over the past 4 years, most recently at $652000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $652000.0 for Q4 2025, up 100.5% from a year ago — trailing twelve months through Dec 2025 was $652000.0 (up 100.5% YoY), and the annual figure for FY2025 was $652000.0, up 100.5%.
  • Retained Earnings for Q4 2025 was $652000.0 at Entrada Therapeutics, up from -$233.9 million in the prior quarter.
  • Over the last five years, Retained Earnings for TRDA hit a ceiling of $652000.0 in Q4 2025 and a floor of -$233.9 million in Q3 2025.
  • Median Retained Earnings over the past 4 years was -$122.9 million (2024), compared with a mean of -$103.5 million.
  • Biggest five-year swings in Retained Earnings: plummeted 66430.26% in 2024 and later surged 100.5% in 2025.
  • Entrada Therapeutics' Retained Earnings stood at -$188.3 million in 2022, then soared by 100.1% to $195000.0 in 2023, then plummeted by 66430.26% to -$129.3 million in 2024, then surged by 100.5% to $652000.0 in 2025.
  • The last three reported values for Retained Earnings were $652000.0 (Q4 2025), -$233.9 million (Q3 2025), and $400000.0 (Q2 2025) per Business Quant data.